N Verses Capital, LLC Shattuck Labs, Inc. Transaction History
N Verses Capital, LLC
- $219 Billion
- Q3 2024
A detailed history of N Verses Capital, LLC transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, N Verses Capital, LLC holds 300 shares of STTK stock, worth $369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 3,300
90.91%
Holding current value
$369
Previous $12.7 Million
91.78%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding STTK
# of Institutions
78Shares Held
26.9MCall Options Held
3.1KPut Options Held
23.9K-
Redmile Group, LLC San Francisco, CA5.62MShares$6.91 Million1.41% of portfolio
-
Prosight Management, LP Dallas, TX4.67MShares$5.74 Million5.63% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.75MShares$3.38 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$3.04 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$2.83 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $52.1M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...